Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

About this update from Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for the treatment of advanced melanoma prior to surgery Data presented at AACR 2026 showed that MDNA113, Medicenna’s anti-PD1-IL-2 bifunctional immunotherapy, was safer even at doses 30-fold higher than a competing anti-PD1-IL-2a-biased agent Strengthened management team by appointment of Dr. Nageatte Ibrahim, MD, as fractional Chief Medical Officer, who brings considerable clinical expertise in cancer immunotherapy from her long tenure at Merck and more recently as the CMO at Innovent Biologics USA Cash runway expected to extend through Q1 calendar 2027, assuming completion of the contemplated structured financing as planned TORONTO and HOUSTON, June 26, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, today reported financial results and corporate highlights for the fiscal year ended March 31, 2026, as well as anticipated corporate milestones. “Fiscal 2026 was a year of important execution across our Superkine pipeline, highlighted by compelling efficacy of MDNA11 in at least three different advanced cancer indications complemented by the impressive pre-clinical profile of MDNA113 in the breakthrough era of bi-functional immunotherapies,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “As we look ahead, we believe that the upcoming MDNA11 clinical data readouts from both the ABILITY-1 and NEO-CYT studies will form the foundation of a broad developmen...

View stock analysis, news, and events for Medicenna Therapeutics Corp.